Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Change in Receivables (2017 - 2020)

Cogent Biosciences (COGT) has 3 years of Change in Receivables data on record, last reported at -$2.0 million in Q1 2020.

  • For Q1 2020, Change in Receivables fell 637.63% year-over-year to -$2.0 million; the TTM value through Dec 2020 reached -$2.0 million, down 702.41%, while the annual FY2020 figure was -$2.0 million, 702.41% down from the prior year.
  • Change in Receivables reached -$2.0 million in Q1 2020 per COGT's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.1 million in Q4 2019 and bottomed at -$2.0 million in Q1 2020.
  • Average Change in Receivables over 3 years is -$92222.2, with a median of $217000.0 recorded in 2018.
  • Peak YoY movement for Change in Receivables: surged 349.8% in 2019, then tumbled 637.63% in 2020.
  • A 3-year view of Change in Receivables shows it stood at $249000.0 in 2018, then soared by 349.8% to $1.1 million in 2019, then crashed by 278.57% to -$2.0 million in 2020.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$2.0 million in Q1 2020, $1.1 million in Q4 2019, and -$612000.0 in Q3 2019.